Review of the current management of atrial fibrillation.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Its prevalence is increasing and accordingly, so is its burden on healthcare systems throughout the world. The pathophysiology of AF is complex and poorly understood, which of itself presents a major challenge to the management of this important condition. AF is associated with increased morbidity and mortality, particularly in patients with underlying left ventricular dysfunction. Once AF occurs, it is often difficult to 'cure' and as such, the major focus of therapy is currently divided essentially between a rate control strategy and a need to revert to and maintain sinus rhythm. Both approaches seek to minimise the associated symptoms and complications. Over the past two decades, numerous pharmacological approaches to the management of AF have been employed, many of which have been shown to be relatively ineffective or confounded by major complications. Accordingly, recent research and interest has focused on non-pharmacological electrophysiological therapies to either cure AF or improve symptoms. This review summarises the current approaches to the management AF and provides some new insights into emerging therapies for this common clinical problem.
Gould
Paul A
PA
Department of Cardiovascular Medicine, Alfred Hospital, Commercial Rd, Melbourne 3004, Victoria, Australia. p.gould@alfred.org.au
Power
John
J
Broughton
Archer
A
Kaye
David M
DM
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D020521:Stroke / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents